Gained therapies included tyrosine kinase inhibitors (TKIs) in the context of EGFR-mutated NSCLC, trastuzumab deruxtecan for ERBB2-mutated NSCLC, ivosidenib for IDH1-mutated CCA, MEK and RAF inhibitor combination therapies for BRAF V600E melanomas, and PARP inhibitors for BRCA2-mutated HGSOC. This evidence concerns the gene BRAF and melanoma.